Correlating NAD(P)H lifetime shifts to tamoxifen resistance in breast cancer cells: A metabolic screening study with time-resolved flow cytometry

Time-resolved flow cytometry (TRFC) was used to measure metabolic differences in estrogen receptor-positive breast cancer cells. This specialty cytometry technique measures fluorescence lifetimes as a single-cell parameter thereby providing a unique approach for high-throughput cell counting and scr...

Full description

Saved in:
Bibliographic Details
Main Authors: Samantha Valentino, Karla Ortega-Sandoval, Kevin D. Houston, Jessica P. Houston
Format: Article
Language:English
Published: World Scientific Publishing 2025-01-01
Series:Journal of Innovative Optical Health Sciences
Subjects:
Online Access:https://www.worldscientific.com/doi/10.1142/S1793545824500202
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832585067086479360
author Samantha Valentino
Karla Ortega-Sandoval
Kevin D. Houston
Jessica P. Houston
author_facet Samantha Valentino
Karla Ortega-Sandoval
Kevin D. Houston
Jessica P. Houston
author_sort Samantha Valentino
collection DOAJ
description Time-resolved flow cytometry (TRFC) was used to measure metabolic differences in estrogen receptor-positive breast cancer cells. This specialty cytometry technique measures fluorescence lifetimes as a single-cell parameter thereby providing a unique approach for high-throughput cell counting and screening. Differences in fluorescence lifetime were detected and this was associated with sensitivity to the commonly prescribed therapeutic tamoxifen. Differences in fluorescence lifetime are attributed to the binding states of the autofluorescent metabolite NAD(P)H. The function of NAD(P)H is well described and in general involves cycling from a reduced to oxidized state to facilitate electron transport for the conversion of pyruvate to lactate. NAD(P)H fluorescence lifetimes depend on the bound or unbound state of the metabolite, which also relates to metabolic transitions between oxidative phosphorylation and glycolysis. To determine if fundamental metabolic profiles differ for cells that are sensitive to tamoxifen compared to those that are resistant, large populations of MCF-7 breast cancer cells were screened and fluorescence lifetimes were quantified. Additionally, metabolic differences associated with tamoxifen sensitivity were measured with a Seahorse HS mini metabolic analyzer (Agilent Technologies Inc. Santa Clara, CA) and confocal imaging. Results show that tamoxifen-resistant breast cancer cells have increased utilization of glycolysis for energy production compared to tamoxifen-sensitive breast cancer cells. This work is impacting because it establishes an early step toward developing a reliable screening technology in which large cell censuses can be differentiated for drug sensitivity in a label-free fashion.
format Article
id doaj-art-5c6f938ebf7f40858bfc3330ea2776b1
institution Kabale University
issn 1793-5458
1793-7205
language English
publishDate 2025-01-01
publisher World Scientific Publishing
record_format Article
series Journal of Innovative Optical Health Sciences
spelling doaj-art-5c6f938ebf7f40858bfc3330ea2776b12025-01-27T05:49:52ZengWorld Scientific PublishingJournal of Innovative Optical Health Sciences1793-54581793-72052025-01-01180110.1142/S1793545824500202Correlating NAD(P)H lifetime shifts to tamoxifen resistance in breast cancer cells: A metabolic screening study with time-resolved flow cytometrySamantha Valentino0Karla Ortega-Sandoval1Kevin D. Houston2Jessica P. Houston3Chemical and Materials Engineering, New Mexico State University, 1040 S Horseshoe Dr., Las Cruces, NM 88003, USAChemical and Materials Engineering, New Mexico State University, 1040 S Horseshoe Dr., Las Cruces, NM 88003, USAChemistry and Biochemistry, New Mexico State University, 1175 N Horseshoe Dr., Las Cruces, NM 88003, USAChemical and Materials Engineering, New Mexico State University, 1040 S Horseshoe Dr., Las Cruces, NM 88003, USATime-resolved flow cytometry (TRFC) was used to measure metabolic differences in estrogen receptor-positive breast cancer cells. This specialty cytometry technique measures fluorescence lifetimes as a single-cell parameter thereby providing a unique approach for high-throughput cell counting and screening. Differences in fluorescence lifetime were detected and this was associated with sensitivity to the commonly prescribed therapeutic tamoxifen. Differences in fluorescence lifetime are attributed to the binding states of the autofluorescent metabolite NAD(P)H. The function of NAD(P)H is well described and in general involves cycling from a reduced to oxidized state to facilitate electron transport for the conversion of pyruvate to lactate. NAD(P)H fluorescence lifetimes depend on the bound or unbound state of the metabolite, which also relates to metabolic transitions between oxidative phosphorylation and glycolysis. To determine if fundamental metabolic profiles differ for cells that are sensitive to tamoxifen compared to those that are resistant, large populations of MCF-7 breast cancer cells were screened and fluorescence lifetimes were quantified. Additionally, metabolic differences associated with tamoxifen sensitivity were measured with a Seahorse HS mini metabolic analyzer (Agilent Technologies Inc. Santa Clara, CA) and confocal imaging. Results show that tamoxifen-resistant breast cancer cells have increased utilization of glycolysis for energy production compared to tamoxifen-sensitive breast cancer cells. This work is impacting because it establishes an early step toward developing a reliable screening technology in which large cell censuses can be differentiated for drug sensitivity in a label-free fashion.https://www.worldscientific.com/doi/10.1142/S1793545824500202Time-resolvedflow cytometryautofluorescencefluorescence lifetimebreast cancermetabolism
spellingShingle Samantha Valentino
Karla Ortega-Sandoval
Kevin D. Houston
Jessica P. Houston
Correlating NAD(P)H lifetime shifts to tamoxifen resistance in breast cancer cells: A metabolic screening study with time-resolved flow cytometry
Journal of Innovative Optical Health Sciences
Time-resolved
flow cytometry
autofluorescence
fluorescence lifetime
breast cancer
metabolism
title Correlating NAD(P)H lifetime shifts to tamoxifen resistance in breast cancer cells: A metabolic screening study with time-resolved flow cytometry
title_full Correlating NAD(P)H lifetime shifts to tamoxifen resistance in breast cancer cells: A metabolic screening study with time-resolved flow cytometry
title_fullStr Correlating NAD(P)H lifetime shifts to tamoxifen resistance in breast cancer cells: A metabolic screening study with time-resolved flow cytometry
title_full_unstemmed Correlating NAD(P)H lifetime shifts to tamoxifen resistance in breast cancer cells: A metabolic screening study with time-resolved flow cytometry
title_short Correlating NAD(P)H lifetime shifts to tamoxifen resistance in breast cancer cells: A metabolic screening study with time-resolved flow cytometry
title_sort correlating nad p h lifetime shifts to tamoxifen resistance in breast cancer cells a metabolic screening study with time resolved flow cytometry
topic Time-resolved
flow cytometry
autofluorescence
fluorescence lifetime
breast cancer
metabolism
url https://www.worldscientific.com/doi/10.1142/S1793545824500202
work_keys_str_mv AT samanthavalentino correlatingnadphlifetimeshiftstotamoxifenresistanceinbreastcancercellsametabolicscreeningstudywithtimeresolvedflowcytometry
AT karlaortegasandoval correlatingnadphlifetimeshiftstotamoxifenresistanceinbreastcancercellsametabolicscreeningstudywithtimeresolvedflowcytometry
AT kevindhouston correlatingnadphlifetimeshiftstotamoxifenresistanceinbreastcancercellsametabolicscreeningstudywithtimeresolvedflowcytometry
AT jessicaphouston correlatingnadphlifetimeshiftstotamoxifenresistanceinbreastcancercellsametabolicscreeningstudywithtimeresolvedflowcytometry